Hjem › Steatotisk leversykdom › New York
Kliniske studier for Steatotisk leversykdom i New York
17 studier for Steatotisk leversykdom søker deltakere på steder i New York.
Byer i New York
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, New York
- 89bio Clinical Study Site, New York
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, Carmel
- 89bio Clinical Study Site, New York
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, New York
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- New York Presbyterian/Weill Cornell, New York
- Columbia University Iriving School of Medicine, New York
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Columbia University Irving Medical Center, New York
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Research Foundation of SUNY - University of Buffalo, Buffalo
- NYU Langone Health, New York
- IMA Clinical Research Manhattan, New York
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Buffalo
- Akero Clinical Study Site, Manhasset
- Akero Clinical Study Site, New York
- og 3 flere
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221188Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Columbia University Irving Medical Center, New York
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 70 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT06354088A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, New York
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
- GSK Investigational Site, New York
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, New York
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. jul. 2026 · NCT06920043Effect of Insulin Lowering on Lipogenesis
- Columbia University Irving Medical Center, New York
RekruttererFase 1
Alder 18 til 65 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT07403604Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Icahn School of Medicine at Mount Sinai, New York
Rekrutterer
Alder 18 til 75 · Alle kjønn · Oppdatert 19. mai 2026 · NCT04054310Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
- Weill Cornell Medicine, New York
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 til 65 · Alle kjønn · Oppdatert 27. feb. 2026 · NCT05332613High Fructose Diet, the Gut Microbiome, and Metabolic Health
- Mount Sinai Morningside, New York
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 25 til 45 · Alle kjønn · Oppdatert 17. des. 2025 · NCT06329544Blood Collection Biorepository for Liver Disease Research
- University at Buffalo, Buffalo General Medical Center, Buffalo
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 7 og eldre · Alle kjønn · Oppdatert 27. aug. 2025 · NCT03025074Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.